Tuesday, 02 January 2024 12:17 GMT

Anx Robotica Announces FDA 510(K) Clearance For Motilicaptm And Motiliscantm: Next-Generation GI Motility Monitoring Solutions


(MENAFN- PR Newswire)

PLANO, Texas, May 27, 2025 /PRNewswire/ -- AnX Robotica, a leader in advanced gastrointestinal diagnostic solutions, is proud to announce the FDA 510(k) clearance of MotiliCapTM and its companion software, MotiliScanTM. This latest clearance marks a significant step forward in GI motility monitoring, offering clinicians an advanced, non-invasive tool for assessing whole-gut transit times with unmatched accuracy and patient comfort.

MotiliCapTM is a next-generation motility capsule designed to evaluate gastrointestinal transit across the stomach, small bowel, and colon. As the most comprehensive solution available, MotiliCap replaces the discontinued SmartPillTM technology, delivering detailed insights into gastric emptying, small bowel transit, and colonic motility-all without radiation or sedation. Data is seamlessly exported to the MotiliScanTM software, where clinicians can visualize pH, pressure, and temperature changes, offering a complete view of GI motility.

"We are thrilled to receive FDA clearance for MotiliCap and MotiliScan, reinforcing our commitment to bringing innovative, patient-friendly diagnostic tools to patients and our customers," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica. "MotiliCap not only fills the void left by SmartPill but enhances it with the latest technologies, customer friendly ease of use and analysis capabilities, empowering clinicians with faster, more accurate diagnostic insights."

The MotiliScanTM software provides intuitive visualization and seamless data analysis, enabling physicians to identify motility disorders and expedite treatment decisions. Designed with both efficiency and precision in mind, MotiliScan allows for customizable reporting, segment-specific analysis, and automated summaries-supporting improved clinical workflows and better patient outcomes.

With this FDA clearance, AnX Robotica continues its mission to revolutionize patient care with advanced GI technologies, building on the success of the NaviCam® platform, which includes NaviCam SB with ProScanTM, NaviCam Capsule/Tether, NaviCam Xpress MCCE System, NaviCam Colon* and IntraMarX.

For more information about MotiliCap, MotiliScan, and the full suite of AnX Robotica's diagnostic technologies, visit anxrobotica.

*Colon Capsule is not available in the United States

MKT-0097 GDGTR3Bv1

SOURCE AnX Robotica

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN27052025003732001241ID1109600751



PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search